ATR相关文献与解析，生知库 | 链接生命科学的每一步

TONSOKU prevents the formation of large tandem duplications and restrains ATR-WEE1 checkpoint activation

TONSOKU可防止形成大型串联重复序列，并抑制ATR-WEE1检查点的激活。

期刊:Nature Communications

影响因子:15.7

doi:10.1038/s41467-026-70906-1

Thomson, Geoffrey; Poulet, Axel; Huang, Yi-Chun; Liao, Hong-Sheng; LeBlanc, Chantal; Jacob, Yannick

ATR

发表日期：2026

文献求助收藏

ATRX loss couples genome instability at a G-rich repeat to dysregulation of human alpha-globin expression.

ATRX 的缺失导致富含 G 的重复序列处的基因组不稳定性与人类 α-珠蛋白表达失调有关。

期刊:Nature Communications

影响因子:15.7

doi:10.1038/s41467-026-69169-7

Shen Yuqi, Gupta Kinam, Tan-Wong Sue Mei, Wen Sean, Fisher Christopher A, Tamon Liezel, Proudfoot Nicholas J, Gibbons Richard J, Higgs Douglas R

Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer.

靶向从头嘧啶合成会使 PARP 抑制剂耐药的卵巢癌对铜介导的 ATR 失活变得脆弱。

期刊:Nature Communications

影响因子:15.7

doi:10.1038/s41467-026-70001-5

Nan Yabing, Wang Kunyu, Hu Menghan, Luo Qingyu, Wu Xiaowei, Yu Xiao, Zhou Xuantong, Chen Li, Li Bin, Cui Zhumei, Liu Zhihua

SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of Telomeres

SMARCAL1 是 ATRX 缺陷型胶质瘤中可靶向合成致死治疗的脆弱位点，这些胶质瘤利用端粒替代延长机制。

期刊:Neuro-Oncology

影响因子:13.4

doi:10.1093/neuonc/noaf300

Brown, Alexandrea; Strickland, Laura M; Erman, Elise N; Pirozzi, Christopher J; Low, Justin T; Diplas, Bill H; Gibson, Emiley; Shobande, Mariah; Khambati, Taher; Krylova, Marharyta; Liu, Heng; McLendon, Roger E; Reitman, Zachary J; Keir, Stephen T; Zou, Lee; Ashley, David M; Waitkus, Matthew S

Energetically equivalent structural transitions in the Rad17-Rad9-Hus1-Rad1-Rhino complex underlie the sequential progression from activation through maintenance to inactivation of the ATR-dependent DNA damage response

Rad17-Rad9-Hus1-Rad1-Rhino复合物中能量等效的结构转变是ATR依赖性DNA损伤反应从激活、维持到失活的顺序进程的基础。

期刊:Nucleic Acids Research

影响因子:13.1

doi:10.1093/nar/gkag093

Fukumoto, Yasunori; Yuki, Ryuzaburo; Ogra, Yasumitsu

ATR and TopBP1 oppose to control dormant origin activity and global replication dynamics, providing a first defense against replication stress

ATR 和 TopBP1 相互拮抗，共同控制休眠复制起始点的活性和整体复制动态，从而构成抵御复制压力的第一道防线。

期刊:Nucleic Acids Research

影响因子:13.1

doi:10.1093/nar/gkag315

Koundrioukoff, Stéphane; Alary, Nathan; Kim, Su-Jung; Collin, Thibault; Toffano, Antoine; Melendez-Garcia, Rodrigo; Wu, Xia; Liu, Yaqun; Gnan, Stefano; El-Hilali, Sami; Brison, Olivier; Rosselli, Filippo; Chen, Chun-Long; Debatisse, Michelle

ATR

发表日期：2026

文献求助收藏

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results

Camonsertib（一种ATRi）联合低剂量吉西他滨治疗伴有DNA损伤反应异常的实体瘤：临床前和Ib期研究结果

期刊:Clinical Cancer Research

影响因子:10.2

doi:10.1158/1078-0432.CCR-25-2240

Rosen, Ezra Y; Yap, Timothy A; Fontana, Elisa; Lee, Elizabeth K; Mahalingam, Devalingam; Højgaard, Martin; Mettu, Niharika B; Cote, Gregory M; Plummer, Ruth; Koehler, Maria; Ulanet, Danielle; Fei, Kezhen; Silverman, Ian M; Schonhoft, Joseph D; Rimkunas, Victoria; Bacque, Emeline S; Gomez, Gabriela; Fretland, Adrian J; Roulston, Anne; Li, Li; Baruah, Prasamit; Zimmermann, Michal; Yang, Julia; Carneiro, Benedito A; Lheureux, Stephanie

Correction for Zhu et al., SETD2-mediated H3K14 trimethylation promotes ATR activation and stalled replication fork restart in response to DNA replication stress

对 Zhu 等人的论文“SETD2 介导的 H3K14 三甲基化促进 ATR 激活和 DNA 复制压力下停滞的复制叉重新启动”的更正

期刊:Proceedings of the National Academy of Sciences of the United States of America

影响因子:9.1

doi:10.1073/pnas.2610804123

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion

BRN2诱导的ATR/STAT3通路或SHLD2亚克隆扩增导致三阴性乳腺癌对新辅助他拉唑帕尼产生耐药性。

期刊:Proceedings of the National Academy of Sciences of the United States of America

影响因子:9.1

doi:10.1073/pnas.2513742123

Abdulkareem, Noor M; Jiang, Yan; Qi, Yuan; Liu, Xuan; Zhang, Xiaomei; Cai, Shirong; Shao, Jiansu; Jeter-Jones, Sabrina; Rinkenbaugh, Amanda L; Cheng, Chun-Chun; Hancock, Faiza; Schwartz, Jill; Litton, Jennifer K; Chang, Jeffrey T; Piwnica-Worms, Helen

REV7 associates with ATRIP and inhibits ATR kinase activity

REV7 与 ATRIP 结合并抑制 ATR 激酶活性

TONSOKU prevents the formation of large tandem duplications and restrains ATR-WEE1 checkpoint activation

TONSOKU可防止形成大型串联重复序列，并抑制ATR-WEE1检查点的激活。

ATRX loss couples genome instability at a G-rich repeat to dysregulation of human alpha-globin expression.

ATRX 的缺失导致富含 G 的重复序列处的基因组不稳定性与人类 α-珠蛋白表达失调有关。

Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer.

靶向从头嘧啶合成会使 PARP 抑制剂耐药的卵巢癌对铜介导的 ATR 失活变得脆弱。

SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use Alternative Lengthening of Telomeres

SMARCAL1 是 ATRX 缺陷型胶质瘤中可靶向合成致死治疗的脆弱位点，这些胶质瘤利用端粒替代延长机制。

Energetically equivalent structural transitions in the Rad17-Rad9-Hus1-Rad1-Rhino complex underlie the sequential progression from activation through maintenance to inactivation of the ATR-dependent DNA damage response

Rad17-Rad9-Hus1-Rad1-Rhino复合物中能量等效的结构转变是ATR依赖性DNA损伤反应从激活、维持到失活的顺序进程的基础。

ATR and TopBP1 oppose to control dormant origin activity and global replication dynamics, providing a first defense against replication stress

ATR 和 TopBP1 相互拮抗，共同控制休眠复制起始点的活性和整体复制动态，从而构成抵御复制压力的第一道防线。

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results

Camonsertib（一种ATRi）联合低剂量吉西他滨治疗伴有DNA损伤反应异常的实体瘤：临床前和Ib期研究结果

Correction for Zhu et al., SETD2-mediated H3K14 trimethylation promotes ATR activation and stalled replication fork restart in response to DNA replication stress

对 Zhu 等人的论文“SETD2 介导的 H3K14 三甲基化促进 ATR 激活和 DNA 复制压力下停滞的复制叉重新启动”的更正

Resistance to neoadjuvant talazoparib in triple-negative breast cancer by BRN2-induced ATR/STAT3 pathways or SHLD2 subclone expansion

BRN2诱导的ATR/STAT3通路或SHLD2亚克隆扩增导致三阴性乳腺癌对新辅助他拉唑帕尼产生耐药性。